Skip to main content

2 January 2014

Smiths Medical has gained a key US Food and Drug Administration (FDA) approval for a customisable infusion system that helps maintain effective epidural analgesia during labour and delivery or with post-operative pain management.

The FDA 510(k) clearance allows Smiths Medical to market its CADD®-Solis pain management system version 3.0 with Programmed Intermittent Bolus (PIB) and Patient Controlled Analgesics (PCA) delivery in the United States.

PIB medication delivery, using the CADD®-Solis v3.0, consistently administers programmed intermittent boluses (doses) that can be supplemented by the patient, improving pain relief and reducing the need for clinical interventions.

The CADD®-Solis ambulatory infusion system, designed for nurses, anesthesiologists, pharmacists and other hospital personnel, is a state-of-the-art system that meets industry recognised standards for advanced error-reduction features in PCA pumps.

General media enquiries

Contact our global media and communications team at:

Tom Steiner

Tom Steiner

Head of External Communications

+44 (0) 20 7004 1600

Email Arrow right icon

Please note – the press team can only answer enquiries from accredited members of the press.

Related articles

Type 8628VL Mechanical Seal

John Crane unveils game-changing mechanical seal, setting new benchmark for ethane pipeline performance

Read our company news as John Crane has launched a new mechanical seal

Find out more Call to action arrow icon
Davinci Gen V Banner Iamge[39]

Smiths Interconnect announces significant contract win

Read our company news as Smiths Interconnect announces a significant contract win

Find out more Call to action arrow icon
Earth View

Smiths Interconnect welcomes new EU-Canada security and defence partnership 

Find out more Call to action arrow icon
Sign up for updates Call to action arrow icon